Oculis (NASDAQ:OCS) Trading Down 3% – Should You Sell?

Shares of Oculis Holding AG (NASDAQ:OCS) traded down 3% on Wednesday . The company traded as low as $18.52 and last traded at $18.41. 7,333 shares traded hands during trading, a decline of 84% from the average session volume of 45,398 shares. The stock had previously closed at $18.97.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Robert W. Baird raised their target price on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. HC Wainwright decreased their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Oculis in a research note on Thursday, March 13th.

Oculis Price Performance

The stock has a market capitalization of $809.49 million, a PE ratio of -9.62 and a beta of 0.01. The stock’s 50 day moving average price is $20.96 and its 200-day moving average price is $17.10. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, equities analysts forecast that Oculis Holding AG will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently made changes to their positions in OCS. abrdn plc raised its holdings in shares of Oculis by 23.0% in the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after acquiring an additional 188,871 shares in the last quarter. Geode Capital Management LLC increased its position in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd bought a new stake in shares of Oculis in the 4th quarter valued at about $225,000. Bellevue Group AG bought a new position in shares of Oculis during the fourth quarter valued at approximately $170,000. Finally, Bank of America Corp DE increased its holdings in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after buying an additional 10,667 shares during the period. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.